Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

Table 2 Effect of SGLT2 inhibitors on clinical outcomes among participants with reduced eGFR

Outcome	No. studies	No. events	Sample size	HR (95% CI)	I², %	P_{Heterogeneity}	P_{Egger test}
Overall (eGFR < 60 mL/min/1.73m²)
MACE	6	2102	20,106	0.82 (0.74–0.91)	8.6	0.363	0.810
Kidney composite	4	530	16,480	0.65 (0.55–0.78)	0.0	0.645	0.771
HHF	6	1125	20,106	0.61 (0.54–0.70)	0.0	0.740	0.099
Cardiovascular death	5	834	18,299	0.86 (0.75–0.98)	0.0	0.912	0.363
Fatal and nonfatal MI	4	320*	15,707	0.75 (0.63–0.90)	0.0	0.480	0.879
Fatal and nonfatal stroke	4	190*	15,707	0.75 (0.55–1.01)	38.3	0.151	0.855
All-cause mortality	3	837	13,668	0.93 (0.81–1.07)	0.0	0.638	0.147
eGFR < 45 mL/min/1.73m²**
MACE	3	347	2437	0.75 (0.60–0.93)	0.0	0.797	0.921
Kidney composite	2	225	1867	0.70 (0.54–0.92)	0.0	0.841	NA
HHF	3	166	2437	0.60 (0.44–0.82)	0.0	0.522	0.193
Cardiovascular death	3	191	2437	0.83 (0.62–1.11)	0.0	0.699	0.925
Fatal and nonfatal MI	2	71	1124	0.70 (0.39–1.26)	28.3	0.238	NA
Fatal and nonfatal stroke	2	38	1124	0.52 (0.23–1.17)	30.2	0.231	NA
All-cause mortality	1	74	570	0.86 (0.54–1.38)	NA	NA	NA

*The number of MI and stroke events were not reported in SCORED and are therefore not included in the table. Likewise, the number of HHF/cardiovascular death events were not reported in SOLOIST-WHF and are not included in the table. CI indicates confidence interval, eGFR estimated glomerular filtration rate, HHF hospitalization for heart failure, MACE major adverse cardiovascular events, HR hazard ratio, MI myocardial infarction, NA not applicable, NR not reported, SCORED Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk, SGLT2 sodium-glucose cotransporter 2, SOLOIST-WHF Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure
**The lower ends of eGFR ranged from 25 to 30 mL/min/1.73 m²

ISSN: 1475-2840